- Market Capitalization, $K 58,523
- Shares Outstanding, K 37,276
- Annual Sales, $ 12,470 K
- Annual Income, $ -53,600 K
- 60-Month Beta 1.61
- Price/Sales 4.78
- Price/Cash Flow N/A
- Price/Book 0.56
|Period||Period Low||Period High||Performance|
| || |
-0.35 (-18.52%)since 05/24/19
| || |
-0.37 (-19.37%)since 03/22/19
| || |
-3.56 (-69.80%)since 06/22/18
Investors need to pay close attention to NewLink Genetics (NLNK) stock based on the movements in the options market lately.
NewLink Genetics Corporation (NASDAQ:NLNK) today announced financial results for the first quarter ended March 31, 2019 and provided an update on clinical activities.
NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will participate in the following investor and medical conferences:
NewLink Genetics Corporation (NASDAQ:NLNK) today announced it will host its first quarter 2019 conference call and webcast at 4:30 PM ET on Wednesday, May 8, 2019, to discuss its first quarter financial...
Cancer is among one of the leading causes of death in the world since many countries are burdened by the lack of access to adequate healthcare, which results in the high number of deaths. In 2018, the...
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Cheniere Energy, Inc. (NYSE:LNG),...
NewLink Genetics Corporation (NASDAQ:NLNK) today announced results from a Phase 2 study of NLG207, a nanoparticle formulation of the topoisomerase 1 inhibitor camptothecin, conducted in conjunction with...
The Zacks Analyst Blog Highlights: ANI, Kamada, Genomic Health and NewLink
The biotech space is witnessing a rally so far in 2019. Here we discuss four stocks that are likely to witness a continuation of the uptrend going ahead.
NewLink Genetics Corporation (NASDAQ:NLNK) today announced that a late-breaking abstract reporting results from a Phase 2 study of NLG207, a nanoparticle formulation of the topoisomerase 1 inhibitor, camptothecin,...